Hemoglobinopathy Treatment Drugs Market, by Drug Type (Analgesics, Antibiotics, ACE Inhibitors, Hydroxyurea, and Others), by Disease Type (Thalassemia, Sickle Cell Disease, and Other Hb Variants Diseases), by Distribution Channel (Hospitals Pharmacies, Re
Description
Hemoglobinopathy Treatment Drugs Market, by Drug Type (Analgesics, Antibiotics, ACE Inhibitors, Hydroxyurea, and Others), by Disease Type (Thalassemia, Sickle Cell Disease, and Other Hb Variants Diseases), by Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028
Hemoglobinopathy is a group of hereditary blood disorders involving an abnormality in the structure of hemoglobin. These disorders include both sickle cell disease (SCD) and thalassemia. Common symptoms of the condition include severe pain, shortness of breath, enlarged spleen, and growth problems in children. Other types of hemoglobinopathies linked to the structural hemoglobin variants are HbS, HbE, and HbC. The highly variable clinical manifestations of the hemoglobinopathies range from mild hypochromic anemia to moderate hematological disease to severe, lifelong, transfusion-dependent anemia with multiorgan involvement. Drugs to treat the symptoms of hemoglobinopathy include analgesics, antibiotics, ACE inhibitors, and hydroxyurea. According to the data of National Center for Biotechnology Information, more than 90% of patients currently survive the adulthood. Optimally treated patients have a projected life span of 50 to 60 years.
Market Dynamics
Increasing incidence and prevalence of sickle cell disease (SCD) is expected to propel growth of the global hemoglobinopathy treatment drugs market over the forecast period. For instance, according to the data published in Centers for Disease Control and Prevention in October 2021, SCD affects around 100,000 Americans every year. Moreover, as per the same source, around 1 in 13 African-American babies are born with sickle cell trait (SCT).
However, failing clinical trials for the treatment of sickle cell anemia are expected to hinder the market growth. For instance, in August 2021, Pfizer Inc. announced that the Phase III Rivipansel pivotal study, to evaluate the efficacy and safety of rivipansel in patients aged six and older with sickle cell disease, failed to achieve its primary or key secondary efficacy endpoints. Moreover, high costs, and difficulties associated with diagnosis of hemoglobinopathies such as lack of proper knowledge and lack of skilled professionals are expected to restrain growth of the market up to certain extent.
Key features of the study:
This report provides in-depth analysis of the global hemoglobinopathy treatment drugs market, market size (US$ Mn), and compound annual growth rate (CAGR (%)) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
It profiles key players in the global hemoglobinopathy treatment drugs market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
Key players covered as a part of this study include Bristol-Myers Squibb Company, GlycoMimetics Inc., Pfizer Inc., Anthera Pharmaceuticals Inc., Eli Lilly and Company, Mast Therapeutics, Daiichi Sankyo Company Ltd., Novartis International AG, Bluebird Bio Inc., HemaQuest Pharmaceuticals Inc., Emmaus Medical Inc., Prolong Pharmaceuticals, Merck & Co., Inc., Medunik USA Inc., Sangamo Therapeutics, Inc., Global Blood Therapeutics, Inc., Alnylam Pharmaceuticals, and Acceleron Pharma, Inc.
Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
The global hemoglobinopathy treatment drugs market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for hemoglobinopathy treatment drugs market, research and consulting firms, new entrants, and financial analysts.
Detailed Segmentation:
Global Hemoglobinopathy Treatment Drugs Market, By Drug Type:
Analgesics
Antibiotics
ACE Inhibitors
Hydroxyurea
Others
Global Hemoglobinopathy Treatment Drugs Market, By Disease Type:
Thalassemia
Sickle Cell Disease
Other Hb Variants Diseases
Global Hemoglobinopathy Treatment Drugs Market, By Distribution Channel:
Hospitals Pharmacies
Retail Pharmacies
Online Pharmacies
Global Hemoglobinopathy Treatment Drugs Market, By Region:
North America
By Country:
U.S.
Canada
By Drug Type:
Analgesics
Antibiotics
ACE Inhibitors
Hydroxyurea
Others
By Disease Type:
Thalassemia
Sickle Cell Disease
Other Hb Variants Diseases
By Distribution Channel:
Hospitals Pharmacies
Retail Pharmacies
Online Pharmacies
Europe
By Country:
U.K.
Germany
Italy
Spain
France
Russia
Rest of Europe
By Drug Type:
Analgesics
Antibiotics
ACE Inhibitors
Hydroxyurea
Others
By Disease Type:
Thalassemia
Sickle Cell Disease
Other Hb Variants Diseases
By Distribution Channel:
Hospitals Pharmacies
Retail Pharmacies
Online Pharmacies
Asia Pacific
By Country:
Australia
India
China
Japan
ASEAN
South Korea
Rest of Asia Pacific
By Drug Type:
Analgesics
Antibiotics
ACE Inhibitors
Hydroxyurea
Others
By Disease Type:
Thalassemia
Sickle Cell Disease
Other Hb Variants Diseases
By Distribution Channel:
Hospitals Pharmacies
Retail Pharmacies
Online Pharmacies
Latin America
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
By Drug Type:
Analgesics
Antibiotics
ACE Inhibitors
Hydroxyurea
Others
By Disease Type:
Thalassemia
Sickle Cell Disease
Other Hb Variants Diseases
By Distribution Channel:
Hospitals Pharmacies
Retail Pharmacies
Online Pharmacies
Middle East
By Country:
GCC Countries
Israel
Rest of Middle East
By Drug Type:
Analgesics
Antibiotics
ACE Inhibitors
Hydroxyurea
Others
By Disease Type:
Thalassemia
Sickle Cell Disease
Other Hb Variants Diseases
By Distribution Channel:
Hospitals Pharmacies
Retail Pharmacies
Online Pharmacies
Africa
By Country/Region:
South Africa
Central Africa
North Africa
By Drug Type:
Analgesics
Antibiotics
ACE Inhibitors
Hydroxyurea
Others
By Disease Type:
Thalassemia
Sickle Cell Disease
Other Hb Variants Diseases
By Distribution Channel:
Hospitals Pharmacies
Retail Pharmacies
Online Pharmacies
Company Profiles
Bristol-Myers Squibb Company*
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
GlycoMimetics Inc.
Pfizer Inc.
Anthera Pharmaceuticals Inc.
Eli Lilly and Company
Mast Therapeutics
Daiichi Sankyo Company Ltd.
Novartis International AG
Bluebird Bio Inc.
HemaQuest Pharmaceuticals Inc.
Emmaus Medical Inc.
Baxter International Inc.
Prolong Pharmaceuticals
Medunik USA Inc.
Sangamo Therapeutics, Inc.
Global Blood Therapeutics, Inc.
Alnylam Pharmaceuticals
Acceleron Pharma, Inc.
“*” marked represents similar segmentation in other categories in the respective section.
Hemoglobinopathy is a group of hereditary blood disorders involving an abnormality in the structure of hemoglobin. These disorders include both sickle cell disease (SCD) and thalassemia. Common symptoms of the condition include severe pain, shortness of breath, enlarged spleen, and growth problems in children. Other types of hemoglobinopathies linked to the structural hemoglobin variants are HbS, HbE, and HbC. The highly variable clinical manifestations of the hemoglobinopathies range from mild hypochromic anemia to moderate hematological disease to severe, lifelong, transfusion-dependent anemia with multiorgan involvement. Drugs to treat the symptoms of hemoglobinopathy include analgesics, antibiotics, ACE inhibitors, and hydroxyurea. According to the data of National Center for Biotechnology Information, more than 90% of patients currently survive the adulthood. Optimally treated patients have a projected life span of 50 to 60 years.
Market Dynamics
Increasing incidence and prevalence of sickle cell disease (SCD) is expected to propel growth of the global hemoglobinopathy treatment drugs market over the forecast period. For instance, according to the data published in Centers for Disease Control and Prevention in October 2021, SCD affects around 100,000 Americans every year. Moreover, as per the same source, around 1 in 13 African-American babies are born with sickle cell trait (SCT).
However, failing clinical trials for the treatment of sickle cell anemia are expected to hinder the market growth. For instance, in August 2021, Pfizer Inc. announced that the Phase III Rivipansel pivotal study, to evaluate the efficacy and safety of rivipansel in patients aged six and older with sickle cell disease, failed to achieve its primary or key secondary efficacy endpoints. Moreover, high costs, and difficulties associated with diagnosis of hemoglobinopathies such as lack of proper knowledge and lack of skilled professionals are expected to restrain growth of the market up to certain extent.
Key features of the study:
This report provides in-depth analysis of the global hemoglobinopathy treatment drugs market, market size (US$ Mn), and compound annual growth rate (CAGR (%)) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
It profiles key players in the global hemoglobinopathy treatment drugs market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
Key players covered as a part of this study include Bristol-Myers Squibb Company, GlycoMimetics Inc., Pfizer Inc., Anthera Pharmaceuticals Inc., Eli Lilly and Company, Mast Therapeutics, Daiichi Sankyo Company Ltd., Novartis International AG, Bluebird Bio Inc., HemaQuest Pharmaceuticals Inc., Emmaus Medical Inc., Prolong Pharmaceuticals, Merck & Co., Inc., Medunik USA Inc., Sangamo Therapeutics, Inc., Global Blood Therapeutics, Inc., Alnylam Pharmaceuticals, and Acceleron Pharma, Inc.
Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
The global hemoglobinopathy treatment drugs market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for hemoglobinopathy treatment drugs market, research and consulting firms, new entrants, and financial analysts.
Detailed Segmentation:
Global Hemoglobinopathy Treatment Drugs Market, By Drug Type:
Analgesics
Antibiotics
ACE Inhibitors
Hydroxyurea
Others
Global Hemoglobinopathy Treatment Drugs Market, By Disease Type:
Thalassemia
Sickle Cell Disease
Other Hb Variants Diseases
Global Hemoglobinopathy Treatment Drugs Market, By Distribution Channel:
Hospitals Pharmacies
Retail Pharmacies
Online Pharmacies
Global Hemoglobinopathy Treatment Drugs Market, By Region:
North America
By Country:
U.S.
Canada
By Drug Type:
Analgesics
Antibiotics
ACE Inhibitors
Hydroxyurea
Others
By Disease Type:
Thalassemia
Sickle Cell Disease
Other Hb Variants Diseases
By Distribution Channel:
Hospitals Pharmacies
Retail Pharmacies
Online Pharmacies
Europe
By Country:
U.K.
Germany
Italy
Spain
France
Russia
Rest of Europe
By Drug Type:
Analgesics
Antibiotics
ACE Inhibitors
Hydroxyurea
Others
By Disease Type:
Thalassemia
Sickle Cell Disease
Other Hb Variants Diseases
By Distribution Channel:
Hospitals Pharmacies
Retail Pharmacies
Online Pharmacies
Asia Pacific
By Country:
Australia
India
China
Japan
ASEAN
South Korea
Rest of Asia Pacific
By Drug Type:
Analgesics
Antibiotics
ACE Inhibitors
Hydroxyurea
Others
By Disease Type:
Thalassemia
Sickle Cell Disease
Other Hb Variants Diseases
By Distribution Channel:
Hospitals Pharmacies
Retail Pharmacies
Online Pharmacies
Latin America
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
By Drug Type:
Analgesics
Antibiotics
ACE Inhibitors
Hydroxyurea
Others
By Disease Type:
Thalassemia
Sickle Cell Disease
Other Hb Variants Diseases
By Distribution Channel:
Hospitals Pharmacies
Retail Pharmacies
Online Pharmacies
Middle East
By Country:
GCC Countries
Israel
Rest of Middle East
By Drug Type:
Analgesics
Antibiotics
ACE Inhibitors
Hydroxyurea
Others
By Disease Type:
Thalassemia
Sickle Cell Disease
Other Hb Variants Diseases
By Distribution Channel:
Hospitals Pharmacies
Retail Pharmacies
Online Pharmacies
Africa
By Country/Region:
South Africa
Central Africa
North Africa
By Drug Type:
Analgesics
Antibiotics
ACE Inhibitors
Hydroxyurea
Others
By Disease Type:
Thalassemia
Sickle Cell Disease
Other Hb Variants Diseases
By Distribution Channel:
Hospitals Pharmacies
Retail Pharmacies
Online Pharmacies
Company Profiles
Bristol-Myers Squibb Company*
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
GlycoMimetics Inc.
Pfizer Inc.
Anthera Pharmaceuticals Inc.
Eli Lilly and Company
Mast Therapeutics
Daiichi Sankyo Company Ltd.
Novartis International AG
Bluebird Bio Inc.
HemaQuest Pharmaceuticals Inc.
Emmaus Medical Inc.
Baxter International Inc.
Prolong Pharmaceuticals
Medunik USA Inc.
Sangamo Therapeutics, Inc.
Global Blood Therapeutics, Inc.
Alnylam Pharmaceuticals
Acceleron Pharma, Inc.
“*” marked represents similar segmentation in other categories in the respective section.
Table of Contents
158 Pages
- 1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- 2. Market Overview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug Type
- Market Snippet, By Disease Type
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
- 3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- COVID-19 Impact on Market
- Pre-COVID 19 Situation
- Post-COVID 19 Situation
- Market Trends
- Epidemiology
- Regulatory Scenario
- Reimbursement Scenario
- New Product Launches/Approvals
- Mergers & Acquisitions
- Porter’s Analysis
- PEST Analysis
- 4. Global Hemoglobinopathy Treatment Drugs Market COVID-19 Impact Analysis
- Pre-COVID 19 Situation
- Post-COVID 19 Situation
- Strategies
- 5. Global Hemoglobinopathy Treatment Drugs Market, By Drug Type, 2017 - 2028, (US$ Million)
- Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
- Analgesics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- Antibiotics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- ACE Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- Hydroxyurea
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- 6. Global Hemoglobinopathy Treatment Drugs Market, By Disease Type, 2017 - 2028, (US$ Million)
- Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
- Thalassemia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- Sickle Cell Disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- Other Hb Variants Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- 7. Global Hemoglobinopathy Treatment Drugs Market, By Distribution Channel, 2017 - 2028, (US$ Million)
- Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
- Hospitals Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- 8. Global Hemoglobinopathy Treatment Drugs Market, By Region, 2017 - 2028, (US$ Million)
- Introduction
- Market Share Analysis, By Region, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, By Region, 2017 - 2028
- Regional Trends
- North America
- Market Size and Forecast, By Drug Type, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Disease Type, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
- U.S.
- Canada
- Europe
- Market Size and Forecast, By Drug Type, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Disease Type, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, By Drug Type, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Disease Type, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
- China
- Japan
- India
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Market Size and Forecast, By Drug Type, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Disease Type, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Africa
- Market Size and Forecast, By Drug Type, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Disease Type, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Country/Region, 2017 - 2028, (US$ Million)
- North Africa
- Central Africa
- South Africa
- Middle East
- Market Size and Forecast, By Drug Type, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Disease Type, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
- GCC Countries
- Israel
- Rest of Middle East
- 9. Competitive Landscape
- Company Profiles
- Bristol-Myers Squibb Company
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- GlycoMimetics Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Pfizer Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Anthera Pharmaceuticals Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Eli Lilly and Company
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Mast Therapeutics
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Daiichi Sankyo Company Ltd.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Novartis International AG
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Bluebird Bio Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- HemaQuest Pharmaceuticals Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Emmaus Medical Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Baxter International Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Prolong Pharmaceuticals
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Medunik USA Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Sangamo Therapeutics, Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Global Blood Therapeutics
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Alnylam Pharmaceuticals
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Acceleron Pharma, Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- 10. Section
- References
- Research Methodology
- About us and Sales Contact
- *Browse 31 market data tables and 27 figures on "Global Hemoglobinopathy Treatment Drugs Market” - forecast to 2028”
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
